Stock Analiz

Bionano Genomics, Inc. BNGO

Biotechnology: Laboratory Analytical Instruments · IPO 2018 · data as of November 13, 2026

$1.00Market cap $14M
Open the interactive analysis →

Bionano Genomics, Inc. (BNGO) is a industrial company listed in the US with a market value of about $14M. In the twelve months to September 30, 2026 it had revenue of $31M and net income of -$30M, a net margin of -96.9%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (2/5); the weakest is shareholder returns (0/5).

Key numbers: 5-year revenue growth of 27% a year, a 5-year average ROIC of -99%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 56% above the current price.

About Bionano Genomics

Bionano Genomics is listed in the US and classified in biotechnology: laboratory analytical instruments, IPO year 2018. Revenue went from $10M in 2017 to $29M in 2025, growth of about 14.7% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 1030% over three years (dilution for shareholders). It spends 40% of revenue on research and development.

Score: 1.2 / 5

Value1/5
Future growth2/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.5
P/B0.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price+56%

Growth and quality

Revenue growth (1 yr)-7.4%
Revenue growth (5 yrs, per year)27.4%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-396.0%
ROIC (5-yr avg.)-99.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$31M$29M$31M$36M$28M$18M$9M$10M$12M$10M
Net income-$30M-$26M-$112M-$232M-$133M-$72M-$41M-$30M-$18M-$23M
Free cash flow——————-$38M-$30M-$20M-$22M
EPS (diluted)$-1.97$-4.85$-88.13$-408.60$-274.88$-156.05$-234.07$-1194.35$-1566.46$-5191.52
Net margin-96.9%-92.6%-364.0%-643.7%-476.9%-402.8%-483.4%-294.3%-154.1%-245.8%
ROIC—-55.3%-213.3%-166.9%-40.5%-20.8%-56.9%-86.3%-84.2%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Bionano Genomics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 56% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Bionano Genomics pay a dividend?

Not currently.

Is Bionano Genomics a good stock to buy?

We do not give buy or sell advice. Bionano Genomics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.